tradingkey.logo
tradingkey.logo
Search

Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs

ReutersSep 3, 2025 11:12 AM
facebooktwitterlinkedin

- Swiss drugmaker Novartis NOVN.S has signed a licensing and options deal with Argo Biopharmaceutical for up to $5.2 billion to gain access to its experimental cardiovascular drugs, the privately held biotech said on Wednesday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI